INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40501, 16416, 'Citalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40502, 16419, 'Citalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40503, 16420, 'Citalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40504, 17272, 'Citalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40505, 21672, 'Citalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40506, 25493, 'Citalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40507, 25638, 'Citalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40508, 27870, 'Citalopram', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40509, 2416, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40510, 2612, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40511, 2614, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40512, 2615, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40513, 2669, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40514, 2671, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40515, 3431, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40516, 3432, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40517, 11143, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40518, 13055, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40519, 16416, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40520, 16419, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40521, 16420, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40522, 17272, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40523, 21672, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40524, 25493, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40525, 25638, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40526, 27870, 'Citalopram', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40527, 2416, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40528, 2612, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40529, 2614, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40530, 2615, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40531, 2669, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40532, 2671, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40533, 3431, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40534, 3432, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40535, 11143, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40536, 13055, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40537, 16416, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40538, 16419, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40539, 16420, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40540, 17272, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40541, 21672, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40542, 25493, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40543, 25638, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40544, 27870, 'Citalopram', 'Long QT Syndrome', 'Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes.  These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia.  Consider periodic EKG assessment on these patients.  Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.', '2', '"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40545, 2416, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40546, 2612, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40547, 2614, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40548, 2615, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40549, 2669, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40550, 2671, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40551, 3431, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40552, 3432, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40553, 11143, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40554, 13055, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40555, 16416, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40556, 16419, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40557, 16420, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40558, 17272, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40559, 21672, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40560, 25493, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40561, 25638, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40562, 27870, 'Citalopram', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40563, 2416, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40564, 2612, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40565, 2614, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40566, 2615, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40567, 2669, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40568, 2671, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40569, 3431, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40570, 3432, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40571, 11143, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40572, 13055, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40573, 16416, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40574, 16419, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40575, 16420, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40576, 17272, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40577, 21672, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40578, 25493, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40579, 25638, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40580, 27870, 'Citalopram', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40581, 2416, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40582, 2612, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40583, 2614, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40584, 2615, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40585, 2669, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40586, 2671, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40587, 3431, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40588, 3432, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40589, 11143, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40590, 13055, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40591, 16416, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40592, 16419, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40593, 16420, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40594, 17272, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40595, 21672, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40596, 25493, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40597, 25638, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40598, 27870, 'Citalopram', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40599, 5425, 'Cimetidine', 'Liver Diseases', 'Cimetidine is partially metabolized by the liver, and to a greater extent when administered orally than when given intravenously.  Although dosage reductions are generally not necessary, therapy with cimetidine should be administered cautiously in patients with liver disease.  Hepatotoxicity has been associated with cimetidine use.  In addition, liver disease appears to be a risk factor for cimetidine-related central nervous system toxicity, which may include mental confusion, agitation, psychosis, depression, anxiety, hallucinations, and disorientation.  These effects are usually reversible within 3 to 4 days after discontinuation of therapy.', '3', 'Taylor DC, Cresswell PR, Bartlett DC "The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog and man." Drug Metab Dispos 6 (1978):  21-30|del Arbol LR, Moreira V, Moreno A, et al. "Bridging hepatic necrosis associated with cimetidine." Am J Gastroenterol 74 (1980):  267-9|Lorenzini I, Jezequel AM, Orlandi F "Cimetidine-induced hepatitis: electron microscopic observations and clinical pattern of liver injury." Dig Dis Sci 26 (1981):  275-80|Delpre G, Kadish U, Livni E "Hepatitis following cimetidine administration." Am J Med Sci 283 (1982):  153-6|Van Steenbergen W, Vanstapel MJ, Desmet V, et al. "Cimetidine-induced liver injury: report of three cases." J Hepatol 1 (1985):  359-68|Schwartz JT, Gyorkey F, Graham DY "Cimetidine hepatitis." J Clin Gastroenterol 8 (1986):  681-6|Lewis JH "Hepatic effects of drugs used in the treatment of peptic ulcer disease." Am J Gastroenterol 82 (1987):  987-1003|Boyd PT, Lepre F, Dickey JD "Chronic active hepatitis associated with cimetidine." Br Med J 298 (1989):  324-5|Ziemniak JA, Bernhard H, Schentag JJ "Hepatic encephalopathy and altered cimetidine kinetics." Clin Pharmacol Ther 34 (1983):  375-82|Gugler R, Muller-Liebenau B, Somogyi A "Altered disposition and availability of cimetidine in liver cirrhotic patients." Br J Clin Pharmacol 14 (1982):  421-30|Grahnen A, Jameson S, Loof L, Tyllstrom J, Lindstrom B "Pharmacokinetics of cimetidine in advanced cirrhosis." Eur J Clin Pharmacol 26 (1984):  347-55|Bianchi Porro G, Lazzaroni M, Lodola E "Blood levels of cimetidine in patients with liver cirrhosis." Int J Clin Pharmacol Ther Toxicol 21 (1983):  374-7|Hashimoto F, Davis RL, Egli D "Hepatitis following treatments with famotidine and then cimetidine." Ann Pharmacother 28 (1994):  37-9|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40600, 5425, 'Cimetidine', 'Peptic Ulcer Hemorrhage', 'Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools.  These might be serious conditions and the diagnosis needs to be ruled out.', '3', '"Product Information. Pepcid (famotidine)." Merck & Co., Inc  (2002):|"Product Information. Axid (nizatidine)." Lilly, Eli and Company  (2002):|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|"Product Information. Tritec (ranitidine bismuth citrate)." Glaxo Wellcome  (2001):|"Product Information. Zantac 75 (ranitidine)." Pfizer U.S. Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40601, 5425, 'Cimetidine', 'Diseases requiring hemodialysis', 'Cimetidine is partially removed by hemodialysis and should be administered after dialysis.', '2', 'Larsson R, Erlanson P, Bodemar G, Norlander B, Fransson L, Strouth L "Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis." Eur J Clin Pharmacol 21 (1982):  325-30|Bjaeldager PA, Jensen JB, Nielsen LP, Larsen NE, Hvidberg EF "Pharmacokinetics of cimetidine in patients undergoing hemodialysis." Nephron 34 (1983):  159-63|Pizzella KM, Moore MC, Schultz RW, Walshe J, Schentag JJ "Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion." Ther Drug Monit 2 (1980):  273-81|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40602, 5425, 'Cimetidine', 'Kidney Diseases', 'Cimetidine and its metabolites are primarily eliminated by the kidney.  The daily dosage should initially be reduced in patients with moderate to severe renal impairment (CrCl < 50 mL/min).  If necessary, the daily dosage may be increased with caution.  Renal dysfunction also appears to be a risk factor for cimetidine-related central nervous system toxicity, which may include mental confusion, agitation, psychosis, depression, anxiety, hallucinations, and disorientation.  These effects are generally reversible within 3 to 4 days after discontinuation of therapy.', '2', 'Larsson R, Bodemar G, Kagedal B "The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function." Acta Med Scand 205 (1979):  87-9|Seidelin R "Cimetidine and renal failure." Postgrad Med J 56 (1980):  440-1|Larsson R, Erlanson P, Bodemar G, Walan A, Bertler A, Fransson L, Norlander B "The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function." Br J Clin Pharmacol 13 (1982):  163-70|Guay DR, Matzke GR, Bockbrader HN, Dancik J "Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function." Clin Pharm 2 (1983):  157-62|Larsson R, Norlander B, Bodemar G, Walan A "Steady-state kinetics and dosage requirements of cimetidine in renal failure." Clin Pharmacokinet 6 (1981):  316-25|"Product Information. Tagamet (cimetidine)." SmithKline Beecham  (2001):|Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994):  393-408', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40603, 21946, 'Cladribine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40604, 30873, 'Cladribine', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40605, 21946, 'Cladribine', 'Bone Marrow Failure Disorders', 'Cladribine induces myelosuppression, primarily affecting lymphocytes and monocytes, however, neutropenia, anemia, and thrombocytopenia have been reported during cladribine therapy.  Myelosuppressive effects are most notable the first month following therapy and may require red blood cell and/or platelet transfusions.  Therapy with cladribine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', 'Betticher DC, Fey MF, Rabaglio M, Cerny T, Hess U, Meier V, Stalder M, Zulian G "Cladribine and severe myelotoxicity." Lancet 342 (1993):  1369|Fleischman RA, Croy D "Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia." Am J Hematol 48 (1995):  293|Bryson HM, Sorkin EM "Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies." Drugs 46 (1993):  872-94|Juliusson G, Liliemark J "Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2''-deoxyadenosine (CdA): relation to opportunistic infections." Blood 79 (1992):  888-94|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40606, 30873, 'Cladribine', 'Bone Marrow Failure Disorders', 'Cladribine induces myelosuppression, primarily affecting lymphocytes and monocytes, however, neutropenia, anemia, and thrombocytopenia have been reported during cladribine therapy.  Myelosuppressive effects are most notable the first month following therapy and may require red blood cell and/or platelet transfusions.  Therapy with cladribine should be administered cautiously in patients whose bone marrow reserve may be severely depressed by prior chemotherapy or whose marrow function is recovering from previous cytotoxic therapy.  Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding.   Close clinical monitoring of hematopoietic function is recommended.', '3', 'Betticher DC, Fey MF, Rabaglio M, Cerny T, Hess U, Meier V, Stalder M, Zulian G "Cladribine and severe myelotoxicity." Lancet 342 (1993):  1369|Fleischman RA, Croy D "Acute onset of severe autoimmune hemolytic anemia after treatment with 2-chlorodeoxyadenosine for chronic lymphocytic leukemia." Am J Hematol 48 (1995):  293|Bryson HM, Sorkin EM "Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies." Drugs 46 (1993):  872-94|Juliusson G, Liliemark J "Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2''-deoxyadenosine (CdA): relation to opportunistic infections." Blood 79 (1992):  888-94|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40607, 21946, 'Cladribine', 'Nervous System Diseases', 'Severe unspecified neurological toxicity has been reported rarely during cladribine therapy administered at therapeutic doses.  Serious neurological toxicity such as irreversible paraparesis and quadriparesis has been reported in patients receiving four to nine times the recommended dosage of cladribine for hairy cell leukemia.  Therapy with cladribine should be administered cautiously to patients with or predisposed to neurological impairment.', '3', '"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40608, 30873, 'Cladribine', 'Nervous System Diseases', 'Severe unspecified neurological toxicity has been reported rarely during cladribine therapy administered at therapeutic doses.  Serious neurological toxicity such as irreversible paraparesis and quadriparesis has been reported in patients receiving four to nine times the recommended dosage of cladribine for hairy cell leukemia.  Therapy with cladribine should be administered cautiously to patients with or predisposed to neurological impairment.', '3', '"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40609, 21946, 'Cladribine', 'Liver Diseases', 'The pharmacokinetic disposition of cladribine has not be fully assessed. The effect of hepatic impairment on the elimination of cladribine is not known.  Therapy with cladribine should be administered cautiously in patient with existing or predisposition to compromised hepatic function.  Clinical monitoring of hepatic function is recommended.', '2', 'Bryson HM, Sorkin EM "Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies." Drugs 46 (1993):  872-94|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40610, 30873, 'Cladribine', 'Liver Diseases', 'The pharmacokinetic disposition of cladribine has not be fully assessed. The effect of hepatic impairment on the elimination of cladribine is not known.  Therapy with cladribine should be administered cautiously in patient with existing or predisposition to compromised hepatic function.  Clinical monitoring of hepatic function is recommended.', '2', 'Bryson HM, Sorkin EM "Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies." Drugs 46 (1993):  872-94|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40611, 21946, 'Cladribine', 'Kidney Diseases', 'The effect of renal impairment on the elimination of cladribine has not been assessed in humans.  Renal toxicity such as acidosis, anuria, elevated serum creatinine has been reported with doses four to nine times the recommended dosage of cladribine for hairy cell leukemia.  Therapy with cladribine should be administered cautiously in patient with compromised renal function.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40612, 30873, 'Cladribine', 'Kidney Diseases', 'The effect of renal impairment on the elimination of cladribine has not been assessed in humans.  Renal toxicity such as acidosis, anuria, elevated serum creatinine has been reported with doses four to nine times the recommended dosage of cladribine for hairy cell leukemia.  Therapy with cladribine should be administered cautiously in patient with compromised renal function.  Clinical monitoring of renal function is recommended.', '2', '"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40613, 2696, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40614, 2697, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40615, 2700, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40616, 6787, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40617, 6949, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40618, 6951, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40619, 6953, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40620, 6954, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40621, 6959, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40622, 6960, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40623, 6962, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40624, 13838, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40625, 14977, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40626, 15794, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40627, 16438, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40628, 16442, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40629, 16443, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40630, 20733, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40631, 20799, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40632, 20800, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40633, 21248, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40634, 21443, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40635, 21444, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40636, 21449, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40637, 21612, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40638, 21613, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40639, 30684, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40640, 30685, 'Clarithromycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40641, 2696, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40642, 2697, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40643, 2700, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40644, 6787, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40645, 6949, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40646, 6951, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40647, 6953, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40648, 6954, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40649, 6959, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40650, 6960, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40651, 6962, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40652, 13838, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40653, 14977, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40654, 15794, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40655, 16438, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40656, 16442, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40657, 16443, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40658, 20733, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40659, 20799, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40660, 20800, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40661, 21248, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40662, 21443, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40663, 21444, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40664, 21449, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40665, 21612, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40666, 21613, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40667, 30684, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40668, 30685, 'Clarithromycin', 'Liver Diseases', 'Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported in patients receiving clarithromycin.  The hepatic dysfunction may be severe but in most cases is reversible.  Fatal outcomes have also been reported and in general have been associated with serious underlying diseases and/or concomitant medications.  Caution and monitoring is advised if using this drug in patients with hepatic impairment.  Treatment must be discontinued immediately if signs and symptoms of hepatitis occur (e.g., anorexia, jaundice, dark urine, pruritus, or tender abdomen).  The use of clarithromycin and combination medications containing this antibiotic are contraindicated in patients with a history of cholestatic jaundice or hepatic impairment associated with the prior use of clarithromycin.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):|"Product Information. Voquezna Triple Pak (amoxicillin/clarithromycin/vonoprazan)." Phathom Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40669, 2696, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40670, 2697, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40671, 2700, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40672, 6787, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40673, 6949, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40674, 6951, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40675, 6953, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40676, 6954, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40677, 6959, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40678, 6960, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40679, 6962, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40680, 13838, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40681, 14977, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40682, 15794, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40683, 16438, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40684, 16442, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40685, 16443, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40686, 20733, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40687, 20799, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40688, 20800, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40689, 21248, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40690, 21443, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40691, 21444, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40692, 21449, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40693, 21612, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40694, 21613, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40695, 30684, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40696, 30685, 'Clarithromycin', 'Kidney Diseases', 'Clarithromycin is primarily eliminated by the kidney and liver.  A decreased dosage or prolonged dosing intervals are recommended in patients with severe renal impairment (CrCl < 30 mL/min).  Dosage adjustments are usually not necessary in patients with mild to moderate renal impairment, although drug accumulation could occur in the presence of concomitant liver disease.  Monitoring is advised.', '2', '"Product Information. Biaxin (clarithromycin)." Abbott Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40697, 2696, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40698, 2697, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40699, 2700, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40700, 6787, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40701, 6949, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40702, 6951, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40703, 6953, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40704, 6954, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40705, 6959, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40706, 6960, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40707, 6962, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40708, 13838, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40709, 14977, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40710, 15794, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40711, 16438, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40712, 16442, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40713, 16443, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40714, 20733, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40715, 20799, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40716, 20800, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40717, 21248, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40718, 21443, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40719, 21444, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40720, 21449, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40721, 21612, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40722, 21613, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40723, 30684, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40724, 30685, 'Clarithromycin', 'Myasthenia Gravis', 'The use of macrolide antibiotics has been reported to exacerbate symptoms of myasthenia gravis and trigger new onset of symptoms of myasthenic syndrome.  Therapy with these agents should be administered cautiously in patients with a history of myasthenia gravis.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax IV (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2022):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40725, 2696, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40726, 2697, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40727, 2700, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40728, 6787, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40729, 6949, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40730, 6951, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40731, 6953, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40732, 6954, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40733, 6959, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40734, 6960, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40735, 6962, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40736, 13838, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40737, 14977, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40738, 15794, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40739, 16438, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40740, 16442, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40741, 16443, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40742, 20733, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40743, 20799, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40744, 20800, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40745, 21248, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40746, 21443, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40747, 21444, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40748, 21449, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40749, 21612, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40750, 21613, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40751, 30684, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40752, 30685, 'Clarithromycin', 'Long QT Syndrome', 'Macrolides have been associated with prolongation of the QT interval and infrequent cases of arrhythmia.  Clarithromycin and erythromycin should be avoided in:  patients with known prolongation of the QT interval, ventricular cardiac arrhythmia, including torsades de pointes; patients with proarrhythmic conditions such as uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia, or receiving other drugs that prolong the QT interval.', '2', '"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40753, 11206, 'Clemastine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|Watemberg NM, Roth KS, Alehan FK, Epstein CE "Central anticholinergic syndrome on therapeutic doses of cyproheptadine." Pediatrics 103 (1999):  158-60|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40754, 11208, 'Clemastine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|Watemberg NM, Roth KS, Alehan FK, Epstein CE "Central anticholinergic syndrome on therapeutic doses of cyproheptadine." Pediatrics 103 (1999):  158-60|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40755, 20516, 'Clemastine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|Watemberg NM, Roth KS, Alehan FK, Epstein CE "Central anticholinergic syndrome on therapeutic doses of cyproheptadine." Pediatrics 103 (1999):  158-60|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40756, 27937, 'Clemastine', 'Anticholinergic Syndrome', 'Antihistamines often have anticholinergic activity, to which elderly patients are particularly sensitive.  Therapy with antihistamines should be administered cautiously, if at all, in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  Conventional, first-generation antihistamines such as the ethanolamines (bromodiphenhydramine, carbinoxamine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, phenyltoloxamine) tend to exhibit substantial anticholinergic effects.  In contrast, the newer, relatively nonsedating antihistamines (e.g., cetirizine, fexofenadine, loratadine) reportedly have low to minimal anticholinergic activity at normally recommended dosages and may be appropriate alternatives.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|Watemberg NM, Roth KS, Alehan FK, Epstein CE "Central anticholinergic syndrome on therapeutic doses of cyproheptadine." Pediatrics 103 (1999):  158-60|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40757, 11206, 'Clemastine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40758, 11208, 'Clemastine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40759, 20516, 'Clemastine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40760, 27937, 'Clemastine', 'Asthma', 'It has been suggested that the anticholinergic effect of antihistamines may reduce the volume and cause thickening of bronchial secretions, resulting in obstruction of respiratory tract.  Some manufacturers and clinicians recommend that therapy with antihistamines be administered cautiously in patients with asthma or chronic obstructive pulmonary disease.', '2', '"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Phenergan (promethazine)." Wyeth-Ayerst Laboratories  (2001):|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Marezine (cyclizine)." Glaxo Wellcome  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|"Product Information. Semprex-D (acrivastine-pseudoephedrine)." Endo Laboratories LLC  (2001):|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):|"Product Information. Tacaryl (methdilazine)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Temaril (trimeprazine)." Allergan Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40761, 11206, 'Clemastine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994):  348-54|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996):  233-52|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40762, 11208, 'Clemastine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994):  348-54|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996):  233-52|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40763, 20516, 'Clemastine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994):  348-54|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996):  233-52|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40764, 27937, 'Clemastine', 'Cardiovascular Diseases', 'Antihistamines may infrequently cause cardiovascular adverse effects related to their anticholinergic and local anesthetic (quinidine-like) activities.  Tachycardia, palpitation, ECG changes, arrhythmias, hypotension, and hypertension have been reported.  Although these effects are uncommon and usually limited to overdosage situations, the manufacturers and some clinicians recommend that therapy with antihistamines be administered cautiously in patients with cardiovascular disease, hypertension, and/or hyperthyroidism.', '2', 'Schuller DE, Turkewitz D "Adverse effects of antihistamines." Postgrad Med 79 (1986):  75-86|"Product Information. Dimetane (brompheniramine)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Chlor-Trimeton (chlorpheniramine)." Schering-Plough|"Product Information. Periactin (cyproheptadine)." Merck & Co., Inc  (2002):|"Product Information. Benadryl (diphenhydramine)." Parke-Davis  (2002):|"Product Information. Tavist (clemastine)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Antivert (meclizine)." Roerig Division  (2001):|"Product Information. Optimine (azatadine)." Schering Corporation  (2001):|Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994):  348-54|"Product Information. Zyrtec (cetirizine)." Pfizer U.S. Pharmaceuticals  (2001):|Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996):  233-52|"Product Information. Drixoral (dextromethorphan)." Schering-Plough  (2001):|"Product Information. Poly-Histine-D (pyrilamine)." Bock Pharmacal Company  (2001):|"Product Information. Vistaril (hydroxyzine)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dramamine (dimenhydrinate)." Pharmacia and Upjohn  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40765, 11206, 'Clemastine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther 16 (1974):  1066-76|Paton DM, Webster DR "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet 10 (1985):  477-97|Rumore MM "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm 18 (1984):  701-7|Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL "Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults." Eur J Clin Pharmacol 22 (1982):  359-65|Simons KJ, Simons FE, Luciuk GH, Frith EM "Urinary excretion of chlorpheniramine and its metabolites in children." J Pharm Sci 73 (1984):  595-9|Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther 35 (1984):  474-9|Blyden GT, Greenblatt DJ, Scavone JM, Shader RI "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol 26 (1986):  529-33|Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG "Pharmacokinetics of diphenhydramine in man." J Pharmacokinet Biopharm 3 (1975):  159-70|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Bruce RB, Turnbull LB, Newman JH, Pitts JE "Metabolism of brompheniramine." J Med Chem 11 (1968):  1031-4|Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ "Human metabolism of cyproheptadine." Drug Metab Dispos 3 (1975):  189-97|Hintze KL, Wold JS, Fischer LJ "Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite." Drug Metab Dispos 3 (1975):  1-9|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|Simons FE, Simons KJ, Frith EM "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." J Allergy Clin Immunol 73 (1984):  69-75|Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ "The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis." J Clin Pharmacol 29 (1989):  809-15', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40766, 11208, 'Clemastine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther 16 (1974):  1066-76|Paton DM, Webster DR "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet 10 (1985):  477-97|Rumore MM "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm 18 (1984):  701-7|Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL "Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults." Eur J Clin Pharmacol 22 (1982):  359-65|Simons KJ, Simons FE, Luciuk GH, Frith EM "Urinary excretion of chlorpheniramine and its metabolites in children." J Pharm Sci 73 (1984):  595-9|Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther 35 (1984):  474-9|Blyden GT, Greenblatt DJ, Scavone JM, Shader RI "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol 26 (1986):  529-33|Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG "Pharmacokinetics of diphenhydramine in man." J Pharmacokinet Biopharm 3 (1975):  159-70|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Bruce RB, Turnbull LB, Newman JH, Pitts JE "Metabolism of brompheniramine." J Med Chem 11 (1968):  1031-4|Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ "Human metabolism of cyproheptadine." Drug Metab Dispos 3 (1975):  189-97|Hintze KL, Wold JS, Fischer LJ "Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite." Drug Metab Dispos 3 (1975):  1-9|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|Simons FE, Simons KJ, Frith EM "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." J Allergy Clin Immunol 73 (1984):  69-75|Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ "The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis." J Clin Pharmacol 29 (1989):  809-15', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40767, 20516, 'Clemastine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther 16 (1974):  1066-76|Paton DM, Webster DR "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet 10 (1985):  477-97|Rumore MM "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm 18 (1984):  701-7|Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL "Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults." Eur J Clin Pharmacol 22 (1982):  359-65|Simons KJ, Simons FE, Luciuk GH, Frith EM "Urinary excretion of chlorpheniramine and its metabolites in children." J Pharm Sci 73 (1984):  595-9|Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther 35 (1984):  474-9|Blyden GT, Greenblatt DJ, Scavone JM, Shader RI "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol 26 (1986):  529-33|Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG "Pharmacokinetics of diphenhydramine in man." J Pharmacokinet Biopharm 3 (1975):  159-70|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Bruce RB, Turnbull LB, Newman JH, Pitts JE "Metabolism of brompheniramine." J Med Chem 11 (1968):  1031-4|Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ "Human metabolism of cyproheptadine." Drug Metab Dispos 3 (1975):  189-97|Hintze KL, Wold JS, Fischer LJ "Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite." Drug Metab Dispos 3 (1975):  1-9|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|Simons FE, Simons KJ, Frith EM "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." J Allergy Clin Immunol 73 (1984):  69-75|Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ "The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis." J Clin Pharmacol 29 (1989):  809-15', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40768, 27937, 'Clemastine', 'Liver Diseases', 'Limited pharmacokinetic data are available for the older, first-generation antihistamines.  Many appear to be primarily metabolized by the liver, and both parent drugs and metabolites are excreted in the urine.  Patients with renal and/or liver disease may be at greater risk for adverse effects from antihistamines due to drug and metabolite accumulation.  Therapy with antihistamines should be administered cautiously in such patients.  Lower initial dosages may be appropriate.', '2', 'Glazko AJ, Dill WA, Young RM, Smith TC, Ogilvie RI "Metabolic disposition of diphenhydramine." Clin Pharmacol Ther 16 (1974):  1066-76|Paton DM, Webster DR "Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines)." Clin Pharmacokinet 10 (1985):  477-97|Rumore MM "Clinical pharmacokinetics of chlorpheniramine." Drug Intell Clin Pharm 18 (1984):  701-7|Huang SM, Athanikar NK, Sridhar K, Huang YC, Chiou WL "Pharmacokinetics of chlorpheniramine after intravenous and oral administration in normal adults." Eur J Clin Pharmacol 22 (1982):  359-65|Simons KJ, Simons FE, Luciuk GH, Frith EM "Urinary excretion of chlorpheniramine and its metabolites in children." J Pharm Sci 73 (1984):  595-9|Meredith CG, Christian CD Jr, Johnson RF, Madhavan SV, Schenker S "Diphenhydramine disposition in chronic liver disease." Clin Pharmacol Ther 35 (1984):  474-9|Blyden GT, Greenblatt DJ, Scavone JM, Shader RI "Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration." J Clin Pharmacol 26 (1986):  529-33|Albert KS, Hallmark MR, Sakmar E, Weidler DJ, Wagner JG "Pharmacokinetics of diphenhydramine in man." J Pharmacokinet Biopharm 3 (1975):  159-70|Simons FE, Frith EM, Simons KJ "The pharmacokinetics and antihistaminic effects of brompheniramine." J Allergy Clin Immunol 70 (1982):  458-64|Bruce RB, Turnbull LB, Newman JH, Pitts JE "Metabolism of brompheniramine." J Med Chem 11 (1968):  1031-4|Porter CC, Arison BH, Gruber VF, Titus DC, Vandenheuvel WJ "Human metabolism of cyproheptadine." Drug Metab Dispos 3 (1975):  189-97|Hintze KL, Wold JS, Fischer LJ "Disposition of cyproheptadine in rats, mice, and humans and identification of a stable epoxide metabolite." Drug Metab Dispos 3 (1975):  1-9|Maddox DE, Reed CE "Clinical pharmacodynamics of antihistamines." Ann Allergy 59 (1987):  43-8|Simons FE, Simons KJ, Frith EM "The pharmacokinetics and antihistaminic of the H1 receptor antagonist hydroxyzine." J Allergy Clin Immunol 73 (1984):  69-75|Simons FE, Watson WT, Chen XY, Minuk GY, Simons KJ "The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis." J Clin Pharmacol 29 (1989):  809-15', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40769, 0, 'Clocortolone (topical)', 'Diabetes Mellitus', 'Corticosteroids can raise blood glucose level by antagonizing the action and suppressing the secretion of insulin, which results in inhibition of peripheral glucose uptake and increased gluconeogenesis.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia.  Systemic absorption of topical corticosteroids may occur depending on the vehicle and concentration of the preparation, the size of the application area, the integrity of the skin, and the duration of administration.  Use of occlusive dressings over the applied areas may also increase percutaneous absorption.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.', '2', 'Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40770, 0, 'Clocortolone (topical)', 'Diaper Rash', 'Topical corticosteroids, especially the potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol), are generally not recommended for use in the treatment of diaper rash.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are usually at the greatest risk for systemic toxicity such as adrenal suppression, Cushing''s syndrome and intracranial hypertension because of their larger skin surface to body mass ratios.  If topical corticosteroids are necessary to treat diaper rash, medium- to low-potency agents should preferably be used, and parents should be advised not to put tight-fitting diapers or plastic pants over the rash, since occlusion of treated area may increase percutaneous drug absorption.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Reymann F, Kehlet H "Hypothalamic-pituitary-adrenocortical function. Association with topical application of betamethasone dipropionate." Arch Dermatol 115 (1979):  362-3|Walsh P, Aeling JL, Huff L, Weston WL "Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids." J Am Acad Dermatol 29 (1993):  501-3|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Ohman EM, Rogers S, Meenan FO, McKenna TJ "Adrenal suppression following low-dose topical clobetasol propionate [published erratum appears in J R Soc Med 1988 May;81(5):308]." J R Soc Med 80 (1987):  422-4|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Novak E, Francom SF, Schlagel CA "Adrenal suppression with high-potency corticosteroid ointment formulations in normal subjects." Clin Ther 6 (1983):  59-71|Gomez EC, Kaminester L, Frost P "Topical halcinonide and betamethasone valerate effects on plasma cortisol: acute and subacute usage studies." Arch Dermatol 113 (1977):  1196-202|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Patel L, Clayton PE, Addison GM, Price DA, David TJ "Adrenal function following topical steroid treatment in children with atopic dermatitis." Br J Dermatol 132 (1995):  950-5|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40771, 0, 'Clocortolone (topical)', 'Adrenocortical Hyperfunction', 'The use of topical corticosteroids may precipitate or aggravate conditions of hyperadrenocorticism.  Systemic absorption of these agents can produce reversible hypothalamic-pituitary-adrenal axis suppression.  Systemic absorption, depends on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Patients with an altered skin barrier or liver failure are also at increased risk.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  The development of symptoms such as menstrual irregularities, acneiform lesions, cataracts and cushingoid features during topical corticosteroid therapy may indicate excessive use.', '2', 'May P, Stein EJ, Ryter RJ, Hirsh FS, Michel B, Levy RP "Cushing syndrome from percutaneous absorption of triamcinolone cream." Arch Intern Med 136 (1976):  612-3|Stoppoloni G, Prisco F, Santinelli R, Sicuranza G, Giordano C "Potential hazards of topical steroid therapy." Am J Dis Child 137 (1983):  1130-1|Ruiz-Maldonado R, Zapata G, Lourdes T, Robles C "Cushing''s syndrome after topical application of corticosteroids." Am J Dis Child 136 (1982):  274-5|Nathan AW, Rose GL "Fatal iatrogenic Cushing''s syndrome." Lancet 1 (1979):  207|Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Salde L, Lassus A "Systemic side-effects of three topical steroids in diseased skin." Curr Med Res Opin 8 (1983):  475-80|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Young CA, Williams IR, MacFarlane IA "Unrecognised Cushing''s syndrome and adrenal suppression due to topical clobetasol propionate." Br J Clin Pract 45 (1991):  61-2|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|Watson WA, Kalb RE, Siskin SB, Freer JP, Krochmal L "The safety of halobetasol 0.05% ointment in the treatment of psoriasis [published erratum appears in Pharmacotherapy 1991;11(3):preceding Table of Contents]." Pharmacotherapy 10 (1990):  107-11|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|Howland WC "Fluticasone propionate: topical or systemic effects?" Clin Exp Allergy 26 ( Suppl (1996):  18-22|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40772, 0, 'Clocortolone (topical)', 'Infections', 'Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Clinically significant local as well as systemic immunosuppressant and anti-inflammatory effects may occur, which can cause or exacerbate an infection.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.  Therapy with topical corticosteroids should be administered cautiously in patients with latent or active infections, particularly if a potent agent is used on a large area for prolonged periods or if occlusive dressings are used.  Effective antimicrobial therapy or other appropriate treatment should be instituted to treat the infection.  If possible, the use of highly potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) should be avoided in children and limited to small areas for 2 weeks in adults.  Occlusive dressings should not be used in patients with skin infection.', '2', 'Macdonald A "Topical corticosteroid preparations. Hazards and side-effects." Br J Clin Pract 25 (1971):  421-5|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40773, 0, 'Clocortolone (topical)', 'Toxic Optic Neuropathy', 'Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves.  Therapy with topical corticosteroids rarely produces these effects but should be administered cautiously nonetheless in patients with a history of cataracts, glaucoma, or increased intraocular pressure, especially when potent agents (e.g., augmented betamethasone, clobetasol, diflorasone, and halobetasol) are used in the periorbital area.  Topical corticosteroids may be systemically absorbed, depending on the vehicle and concentration of the preparation, the size of the application area, the duration of administration, and whether or not occlusive dressings are used.  Given equivalent doses, small children are generally at the greatest risk because of their larger skin surface to body mass ratios.', '2', 'Kitazawa Y "Increased intraocular pressure induced by corticosteroids." Am J Ophthalmol 82 (1976):  492-5|Eisenlohr JE "Glaucoma following the prolonged use of topical steroid medication to the eyelids." J Am Acad Dermatol 8 (1983):  878-81|Carruthers JA, Staughton RC, August PJ "Penetration of topical steroid preparations." Arch Dermatol 113 (1977):  522|Aggarwal RK, Potamitis T, Chong NH, Guarro M, Shah P, Kheterpal S "Extensive visual loss with topical facial steroids." Eye 7(Pt 5) (1993):  664-6|Cubey RB "Glaucoma following the application of corticosteroid to the skin of the eyelids." Br J Dermatol 95 (1976):  207-8|Pace WE "Topical corticosteroids." Can Med Assoc J 108 (1973):  11 passim|"Product Information. Lidex (fluocinonide topical)." Syntex Laboratories Inc  (2022):|"Product Information. Synalar (fluocinolone topical)." Syntex Laboratories Inc  (2001):|"Product Information. Halog (halcinonide topical)." Bristol-Myers Squibb|"Product Information. Ultravate (halobetasol topical)." Apothecon Inc  (2022):|"Product Information. Cutivate (fluticasone)." Glaxo Wellcome  (2001):|"Product Information. Diprolene (betamethasone topical)." Schering Corporation  (2001):|"Product Information. Temovate (clobetasol topical)." Glaxo Wellcome|"Product Information. Decadron Phosphate, Topical (dexAMETHasone topical)." Merck & Co., Inc  (2001):|"Product Information. Aclovate (alclometasone topical)." Glaxo Wellcome  (2001):|"Product Information. Cyclocort (amcinonide topical)." Fujisawa  (2001):|"Product Information. Desowen (desonide topical)." Galderma Laboratories Inc  (2001):|"Product Information. Topicort (desoximetasone topical)." Hoechst Marion Roussel|"Product Information. Psorcon (diflorasone topical)." Rhone Poulenc Rorer  (2001):|"Product Information. Cordran (flurandrenolide topical)." Oclassen Pharmaceuticals Inc  (2001):|"Product Information. Elocon (mometasone topical)." Schering Corporation  (2001):|"Product Information. Proctocream HC (hydrocortisone-pramoxine topical)." Schwarz Pharma  (2022):|"Product Information. Aristocort Topical (triamcinolone topical)." Fujisawa  (2001):|"Product Information. Kenalog (triamcinolone topical)." Westwood Squibb Pharmaceutical Corporation  (2001):|"Product Information. Dermatop (prednicarbate topical)." Janssen Pharmaceuticals  (2001):|"Product Information. Pandel (hydrocortisone topical)." Savage Laboratories  (2001):|"Product Information. Cloderm (clocortolone topical)." Hermal Pharmaceutical Labs Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40774, 2758, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40775, 2759, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40776, 2761, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40777, 2764, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40778, 2767, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40779, 2770, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40780, 2771, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40781, 2775, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40782, 2776, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40783, 3080, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40784, 3290, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40785, 3291, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40786, 3293, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40787, 3294, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40788, 3295, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40789, 7965, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40790, 7966, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40791, 12025, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40792, 13474, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40793, 13475, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40794, 13476, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40795, 13714, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40796, 13715, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40797, 13716, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40798, 16235, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40799, 16511, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40800, 16512, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40801, 16514, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40802, 16516, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40803, 16517, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40804, 16518, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40805, 16523, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40806, 16526, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40807, 16527, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40808, 16531, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40809, 21455, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40810, 22549, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40811, 28883, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40812, 28907, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40813, 29355, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40814, 32659, 'Clindamycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40815, 2758, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40816, 2759, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40817, 2761, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40818, 2764, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40819, 2767, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40820, 2770, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40821, 2771, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40822, 2775, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40823, 2776, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40824, 3080, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40825, 3290, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40826, 3291, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40827, 3293, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40828, 3294, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40829, 3295, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40830, 7965, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40831, 7966, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40832, 12025, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40833, 13474, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40834, 13475, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40835, 13476, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40836, 13714, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40837, 13715, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40838, 13716, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40839, 16235, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40840, 16511, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40841, 16512, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40842, 16514, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40843, 16516, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40844, 16517, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40845, 16518, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40846, 16523, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40847, 16526, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40848, 16527, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40849, 16531, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40850, 21455, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40851, 22549, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40852, 28883, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40853, 28907, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40854, 29355, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40855, 32659, 'Clindamycin', 'Premature Birth', 'Parenteral medications formulated in multidose vials often contain benzyl alcohol as a preservative.  Their use is considered by drug manufacturers to be contraindicated in neonates, particularly premature infants and infants of low birth weight.  When used in bacteriostatic saline intravascular flush and endotracheal tube lavage solutions, benzyl alcohol has been associated with fatalities and severe respiratory and metabolic complications in low-birth-weight premature infants.  Thus, single-dose formulations should always be used in infants whenever possible.  However, many experts feel that, in the absence of benzyl alcohol-free equivalents, the amount of the preservative present in these formulations should not necessarily preclude their use if they are clearly indicated.  The American Academy of Pediatrics considers benzyl alcohol in low doses (such as when used as a preservative in some medications) to be safe for newborns.  However, the administration of high dosages of these medications must take into account the total amount of benzyl alcohol administered.  The level at which toxicity may occur is unknown.', '3', '"Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn  (2001):|"Product Information. Mesnex (mesna)." Bristol-Myers Squibb  (2001):|"Product Information. Mivacron (mivacurium)." Glaxo Wellcome  (2001):|"Product Information. Nuromax (doxacurium)." Glaxo Wellcome  (2001):|"Product Information. Tracrium (atracurium)." Glaxo Wellcome  (2001):|""Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. Available from: URL: http://www.aap.org/policy/re9706.html." Pediatrics 99 (1997):  268-78', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40856, 2758, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40857, 2759, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40858, 2761, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40859, 2764, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40860, 2767, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40861, 2770, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40862, 2771, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40863, 2775, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40864, 2776, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40865, 3080, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40866, 3290, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40867, 3291, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40868, 3293, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40869, 3294, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40870, 3295, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40871, 7965, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40872, 7966, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40873, 12025, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40874, 13474, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40875, 13475, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40876, 13476, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40877, 13714, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40878, 13715, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40879, 13716, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40880, 16235, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40881, 16511, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40882, 16512, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40883, 16514, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40884, 16516, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40885, 16517, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40886, 16518, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40887, 16523, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40888, 16526, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40889, 16527, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40890, 16531, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40891, 21455, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40892, 22549, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40893, 28883, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40894, 28907, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40895, 29355, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40896, 32659, 'Clindamycin', 'Liver Diseases', 'Clindamycin is primarily metabolized by the liver.  The serum concentration of clindamycin may be increased and the half-life prolonged in patients with severely impaired hepatic function.  In addition, jaundice and liver enzyme abnormalities may occur during use of the drug.  Therapy with clindamycin should be administered cautiously in patients with liver disease.  Dosage adjustments may not be necessary when administered every 8 hours.  However, serum concentrations should be monitored during high-dose therapy, and periodic liver function tests should be performed during prolonged therapy.', '2', 'Avant GR, Schenker S, Alford RH "The effect of cirrhosis on the disposition and elimination of clindamycin." Dig Dis 20 (1975):  223-30|Hinthorn DR, Baker LH, Romig DA, et al. "Use of clindamycin in patients with liver disease." Antimicrob Agents Chemother 9 (1976):  498-501|Eng RH, Gorski S, Person A, et al. "Clindamycin elimination in patients with liver disease." J Antimicrob Chemother 8 (1981):  277-81|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40897, 2758, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40898, 2759, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40899, 2761, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40900, 2764, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40901, 2767, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40902, 2770, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40903, 2771, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40904, 2775, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40905, 2776, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40906, 3080, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40907, 3290, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40908, 3291, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40909, 3293, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40910, 3294, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40911, 3295, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40912, 7965, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40913, 7966, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40914, 12025, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40915, 13474, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40916, 13475, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40917, 13476, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40918, 13714, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40919, 13715, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40920, 13716, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40921, 16235, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40922, 16511, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40923, 16512, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40924, 16514, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40925, 16516, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40926, 16517, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40927, 16518, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40928, 16523, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40929, 16526, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40930, 16527, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40931, 16531, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40932, 21455, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40933, 22549, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40934, 28883, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40935, 28907, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40936, 29355, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40937, 32659, 'Clindamycin', 'Kidney Diseases', 'Clindamycin is eliminated by the kidney to a limited extent.  Therapy with clindamycin should be administered cautiously in patients with severely impaired renal function.  Dosage adjustments are probably not necessary.  However, serum clindamycin concentrations should be monitored during high-dose therapy, and periodic renal function tests should be performed during prolonged therapy.', '2', 'Eastwood JB, Gower PE "A study of the pharmacokinetics of clindamycin in normal subjects and patients with chronic renal failure." Postgrad Med J 50 (1974):  710-2|Peddie BA, Dann E, Bailey RR "The effect of impairment of renal function and dialysis on the serum and urine levels of clindamycin." Aust N Z J Med 5 (1975):  198-202|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40938, 0, 'Clomifene', 'Metrorrhagia', 'The use of clomiphene is contraindicated in patients with undiagnosed, abnormal genital bleeding.  Patients should be evaluated to ensure that neoplastic lesions are not present.', '3', '"Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40939, 0, 'Clomifene', 'Liver Diseases', 'The use of clomiphene is contraindicated in patients with liver disease or history of hepatic dysfunction..  Clomiphene undergoes enterohepatic circulation and is metabolized by the liver.  The serum concentration of clomiphene may be increased and the half-life prolonged in patients with compromised hepatic function.', '3', '"Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40940, 0, 'Clomifene', 'Pituitary Diseases', 'The use of clomiphene is contraindicated in patients with uncontrolled thyroid or adrenal dysfunction or an organic intracranial lesion such as a pituitary tumor.  Clomiphene interacts with estrogen receptors in various tissues, including the pituitary, the response of which is an increase in the release of pituitary gonadotropins.', '3', '"Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40941, 0, 'Clomifene', 'Adrenal Insufficiency', 'The use of clomiphene is contraindicated in patients with uncontrolled adrenal function.  Alterations of adrenal function can impede pregnancy.  Clomiphene therapy can result in alteration in steroid synthesis and/or fluid regulation.', '3', '"Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40942, 0, 'Clomifene', 'Hyperlipidemias', 'Cases of hypertriglyceridemia have been reported in patients receiving clomiphene treatment.  Preexisting or family history of hyperlipidemia and use of higher than recommended dose and/or longer duration of treatment with clomiphene citrate are associated with a risk of hypertriglyceridemia.  Periodic monitoring of plasma triglycerides is recommended in patients with preexisting or family history of hyperlipidemia.  Pretreatment screening of triglyceride levels is recommended in patients initiating clomiphene citrate therapy.', '2', '"Product Information. ClomiPHENE Citrate (clomiPHENE)." Teva Pharmaceuticals USA  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40943, 0, 'Clobazam', 'Alcoholic Intoxication', 'The use of benzodiazepines with alcohol is not recommended.  Patients with acute alcohol intoxication exhibit depressed vital signs.  The central nervous system depressant effects of benzodiazepines may be additive with those of alcohol, and severe respiratory depression and death may occur.  Therapy with benzodiazepines should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Versed (midazolam)." Roche Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40944, 0, 'Clobazam', 'Substance-Related Disorders', 'Benzodiazepines have the potential to cause dependence and abuse.  Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages.  However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms.  Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines.  It may be prudent to refrain from dispensing large quantities of medication to these patients.  After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule.  If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.', '3', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):|"Product Information. Byfavo (remimazolam)." Acacia Pharma, Inc  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40945, 0, 'Clobazam', 'Depressive Disorder', 'Benzodiazepines depress the central nervous system and may cause or exacerbate mental depression and cause suicidal behavior and ideation.  Episodes of mania and hypomania have also been reported in depressed patients treated with some of these agents.  Therapy with benzodiazepines should be administered cautiously in patients with a history of depression or other psychiatric disorders.  Patients should be monitored for any changes in mood or behavior.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '2', '"Product Information. Xanax (alprazolam)." Pharmacia and Upjohn  (2002):|"Product Information. Valium (diazepam)." Roche Laboratories  (2002):|"Product Information. Ativan (lorazepam)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Serax (oxazepam)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Restoril (temazepam)." Sandoz Pharmaceuticals Corporation  (2001):|"Product Information. Halcion (triazolam)." Pharmacia and Upjohn  (2001):|"Product Information. Dalmane (flurazepam)." Roche Laboratories  (2001):|"Product Information. Tranxene (clorazepate)." Abbott Pharmaceutical  (2001):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Prosom (estazolam)." Abbott Pharmaceutical  (2022):|"Product Information. Librium (chlordiazepoxide)." Roche Laboratories  (2001):|"Product Information. Doral (quazepam)." Wallace Laboratories  (2001):|"Product Information. Onfi (clobazam)." Lundbeck Inc  (2011):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40946, 0, 'Clofazimine', 'Gastrointestinal Diseases', 'The use of clofazimine has been associated with severe abdominal symptoms including splenic infarction, bowel obstruction, and GI bleeding.  Death has been reported following severe abdominal symptoms.  Crystalline deposits have been found in the intestinal mucosa, liver, gallbladder, bile, spleen, adrenals, subcutaneous fat, mesenteric lymph nodes, muscles, bone and skin.  Clofazimine should be administered cautiously in patients with GI problems such as abdominal pain and diarrhea.', '2', 'Merrett MN, King RW, Farrell KE, Zeimer H, Guli E "Orange/black discolouration of the bowel (at laparotomy) due to clofazimine." Aust N Z J Surg 60 (1990):  638-9|Belaube P, Devaux J, Pizzi M, Boutboul R, Privat Y "Small bowel deposition of crystals associated with the use of clofazimine (Lamprene) in the treatment of prurigo nodularis." Int J Lepr Other Mycobact Dis 51 (1983):  328-30|Venencie PY, Cortez A, Orieux G, Jost JL, Chomette G, Puissant A "Clofazimine enteropathy." J Am Acad Dermatol 15 (1986):  290-1|Holdiness MR "Clinical pharmacokinetics of clofazimine: a review." Clin Pharmacokinet 16 (1989):  74-85|"Product Information. Lamprene (clofazimine)." Novartis Pharmaceuticals  (2002):|Ravi S, Holubka J, Veneri R, Youn K, Khatib R "Clofazimine-induced eosinophilic gastroenteritis in AIDS." Am J Gastroenterol 88 (1993):  612-3|Chong PY, Ti TK "Severe abdominal pain in low dosage clofazimine." Pathology 25 (1993):  24-6', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40947, 0, 'Clofazimine', 'Kidney Diseases', 'Clofazimine is primarily eliminated by the kidney.  Approximately 99% of clofazimine is excreted unchanged in the urine.  Therapy with clofazimine should be administered cautiously and may a longer dosing interval in patients with renal dysfunction.', '2', 'Holdiness MR "Clinical pharmacokinetics of clofazimine: a review." Clin Pharmacokinet 16 (1989):  74-85', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40948, 0, 'Clofibrate', 'Cardiotoxicity', 'The use of clofibrate has been associated with an increased incidence of adverse cardiovascular effects, including cardiac arrhythmias, intermittent claudication, thromboembolic events, and angina.  Because of these risks, as well as the lack of substantial evidence demonstrating a beneficial effect on cardiovascular mortality, therapy with clofibrate should be considered and administered cautiously in patients with a history of cardiovascular or cerebrovascular disease.', '3', '"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40949, 0, 'Clofibrate', 'Liver Diseases', 'The use of clofibrate is considered by the manufacturer to be contraindicated in patients with clinically significant hepatic and/or renal impairment.  The protein-binding of clofibrate may be reduced under these circumstances, resulting in higher concentrations of free (active) drug.  Increased adverse effects, including rhabdomyolysis (with or without secondary renal failure) and severe hyperkalemia, have been associated with preexisting renal insufficiency, presumably due to both decreased drug clearance and protein-binding.  If clofibrate is used in patients with impaired renal and/or hepatic function, reduced dosages should be considered.  Close clinical monitoring is recommended during therapy.', '3', 'Gugler R, Kurten JW, Jensen CJ, et al. "Clofibrate disposition in renal failure and acute and chronic liver disease." Eur J Clin Pharmacol 15 (1979):  341-7|Cumming A "Acute renal failure and interstitial nephritis after clofibrate treatment." Br Med J 281 (1980):  1529-30|Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Ferry N, Bernard N, Pozet N, Gardes E, Cuisinaud G, Labeeuw M, Zech PY, Sassard J "The influence of renal insufficiency and haemodialysis on the kinetics of ciprofibrate." Br J Clin Pharmacol 28 (1989):  675-81|Viikari J, Anttila M, Kasanen A "The use of clofibrate in patients with renal insufficiency." Int J Clin Pharmacol Ther Toxicol 21 (1983):  77-80|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Verbeeck RK "Glucuronidation and disposition of drug glucuronides in patients with renal failure: a review." Drug Metab Dispos 10 (1982):  87-9|Faed EM, McQueen EG "Plasma half-life of clofibric acid in renal failure." Br J Clin Pharmacol 7 (1979):  407-10|Cayen MN "Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man." Pharmacol Ther 29 (1985):  157-204|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|Miller DB, Spence JD "Clinical pharmacokinetics of fibric acid derivatives (fibrates)." Clin Pharmacokinet 34 (1998):  155-62', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40950, 0, 'Clofibrate', 'Liver Cirrhosis, Biliary', 'The use of fibric acid derivatives is contraindicated in patients with primary biliary cirrhosis.  These agents may further raise the already elevated cholesterol in these patients.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40951, 0, 'Clofibrate', 'Cholelithiasis', 'The use of fibric acid derivatives is contraindicated in patients with gallbladder disease.  A significantly increased incidence of cholelithiasis has been observed in patients treated with the fibric acid derivative, clofibrate, presumably because of increased cholesterol excretion into the bile.  Based on two separate studies (the WHO study and the Coronary Drug Project study), clofibrate use was associated with twice the risk of developing cholelithiasis and cholecystitis requiring surgery.  Due to their structural and pharmacologic similarities, use of other fibric acid derivatives may be expected to carry the same risk.', '3', '"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40952, 0, 'Clofibrate', 'Rhabdomyolysis', 'Severe myopathy, including rhabdomyolysis with acute renal failure secondary to myoglobinuria, has been reported rarely with the use of fibric acid derivatives.  The myopathy may be dose-related and is characterized by muscle aches and/or weakness in conjunction with increases in creatine phosphokinase (CPK) values exceeding 10 times the upper limit of normal.  Therapy with fibric acid derivatives should be administered cautiously in patients with preexisting myopathy or a myoneural disorder, since it may delay the recognition or confound the diagnosis of a drug-induced musculoskeletal effect.  Patients should be advised to report promptly any unusual muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.  Periodic CPK determinations may be considered in some patients, although the value of such monitoring is uncertain.  Therapy should be withdrawn if markedly elevated CPK levels occur or if drug-related myopathy is diagnosed or suspected.', '3', 'Pokroy N, Ress S, Gregory MC "Clofibrate-induced complications in renal disease: a case report." S Afr Med J 52 (1977):  806-8|Abourizk N, Khalil BA, Bahuth N, Afifi AK "Clofibrate-induced muscular syndrome. Report of a case with clinical, electromyographic and pathologic observations." J Neurol Sci 42 (1979):  1-9|Rush P, Baron M, Kapusta M "Clofibrate myopathy: a case report and a review of the literature." Semin Arthritis Rheum 15 (1986):  226-9|Goldman JA, Fishman AB, Lee JE, Johnson RJ "The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis ." Arthritis Rheum 32 (1989):  358-9|Fusella J, Strosberg JM "Polymyositis exacerbated by gemfibrozil ." J Rheumatol 17 (1990):  572-3|Pierce LR, Wysowski DK, Gross TP "Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy." JAMA 264 (1990):  71-5|Chow LT, Chow WH "Acute compartment syndrome: an unusual presentation of gemfibrozil induced myositis." Med J Aust 158 (1993):  48-9|"Product Information. Lopid (gemfibrozil)." Parke-Davis  (2002):|Blane GF "Comparative toxicity and safety profile of fenofibrate and other fibric acid derivatives." Am J Med 83 (1987):  26-36|Roberts WC "Safety of fenofibrate--US and worldwide experience." Cardiology 76 (1989):  169-79|Dealava E, Sola JJ, Lozano MD, Pardomindan FJ "Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants." Nephron 66 (1994):  242-3|Shepherd J "Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety." Eur Heart J 16 (1995):  5-13|Thompson CH, Irish A, Kemp GJ, Taylor DJ, Radda GK "Skeletal muscle metabolism before and after gemfibrozil treatment in dialysed patients with chronic renal failure." Clin Nephrol 45 (1996):  386-9|"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):|Gorriz JL, Sancho A, Lopezmartin JM, Alcoy E, Catalan C, Pallardo LM "Rhabdomyolysis and acute renal failure associated with gemfibrozil therapy." Nephron 74 (1996):  437-8|"Product Information. Tricor (fenofibrate)." Abbott Pharmaceutical  (2001):|Duell PB, Connor WE, Illingworth DR "Rhabdomyolysis after taking atorvastatin with gemfibrozil." Am J Cardiol 81 (1998):  368-9|Kirchgassler KU, Schmitz H, Bach G "Effectiveness and tolerability of 12-week treatment with micronised fenofibrate 200mg in a drug-monitoring programme involving 9884 patients with dyslipidaemia." Clin Drug Invest 15 (1998):  197-204|Iliadis EA, Rosenson RS "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia." Clin Cardiol 22 (1999):  25-8|van Puijenbroek EP, Du Buf-Vereijken PW, Spooren PF, van Doormaal JJ "Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil." J Intern Med 240 (1996):  403-4|Pogson GW, Kindred LH, Carper BG "Rhabdomyolysis and renal failure associated with cerivastatin-gemfibrozil combination therapy." Am J Cardiol 83 (1999):  1146|"Product Information. Trilipix (fenofibric acid)." Abbott Pharmaceutical  (2008):|"Product Information. Fibricor (fenofibric acid)." AR Scientific Inc  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40953, 0, 'Clofibrate', 'Peptic Ulcer', 'Reactivation of peptic ulcer has been reported during treatment with clofibrate.  Although a causal relationship has not been established, therapy with clofibrate should be administered cautiously in patients with a history of peptic ulcers.', '2', '"Product Information. Atromid-S (clofibrate)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40954, 12320, 'Clioquinol (topical)', 'Toxic Optic Neuropathy', 'The use of oral clioquinol (no longer marketed in the U.S.), generally at high dosages for prolonged periods, has resulted in ocular and neurologic toxicity, including optic neuritis, optic atrophy, and subacute myelo-optic neuropathy.  Because the drug is systemically absorbed following topical administration to the skin, therapy with topical clioquinol should be administered cautiously in patients with peripheral neuropathy, optic neuritis, or preexisting visual defects.  The use of occlusive dressings may substantially increase percutaneous absorption and should be avoided.  All patients should be advised to immediately discontinue the drug and contact a physician if visual disturbances occur or are exacerbated during therapy.  Clioquinol is not recommended for use in children and is contraindicated for those under 2 years of age.', '2', '"Product Information. Vioform (clioquinol topical)." Ciba-Geigy Pharmaceuticals, East Hanover, NJ.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40955, 12320, 'Clioquinol (topical)', 'Hypothyroidism', 'Percutaneous absorption of clioquinol topical occurs.  Protein-bound serum iodine levels may be increased during treatment with clioquinol topical and may interfere with certain thyroid function tests.  Therapy with clioquinol topical should be used cautiously in patients with thyroid dysfunction.', '2', '"Product Information. Vioform (clioquinol topical)." Ciba-Geigy Pharmaceuticals, East Hanover, NJ.', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40956, 0, 'Clevidipine', 'Aortic Valve Stenosis', 'Clevidipine is contraindicated in patients with severe aortic stenosis because afterload reduction can be expected to reduce myocardial oxygen delivery.', '3', '"Product Information. Cleviprex (clevidipine)." The Medicines Company  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40957, 0, 'Clevidipine', 'Hyperlipidemias', 'Clevidipine is contraindicated in patients with defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis if it is accompanied by hyperlipidemia.', '3', '"Product Information. Cleviprex (clevidipine)." The Medicines Company  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40958, 0, 'Clevidipine', 'Heart Failure', 'The use of clevidipine can produce negative inotropic effects and exacerbate heart failure.  It is recommended to monitor heart failure patients carefully during treatment with this agent.', '2', '"Product Information. Cleviprex (clevidipine)." The Medicines Company  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40959, 0, 'Clevidipine', 'Hypotension', 'The use of clevidipine may produce systemic hypotension and reflex tachycardia.  Dosage reduction may be necessary.  There is limited experience with short-duration therapy with beta-blockers as a treatment for clevidipine -induced tachycardia; therefore, beta-blocker use for this purpose is not recommended.  Close monitoring is recommended.', '2', '"Product Information. Cleviprex (clevidipine)." The Medicines Company  (2008):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40960, 720, 'Clomipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'Remick RA, Campos PE, Misri S, Miles JE, Van Wyck, Fleet J "A comparison of the safety and efficacy of buproprion HCL and amitriptyline HCL in depressed outpatients." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  523-7|Guy W, McEvoy JM, Ban TA, Wilson WH, Pate K "A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology." Pharmacotherapy 3 (1983):  45-51|Bryant SG, Fisher S, Kluge RM "Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system." J Clin Psychopharmacol 7 (1987):  78-82|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Rudorfer MV, Young RC "Anticholinergic effects and plasma desipramine levels." Clin Pharmacol Ther 28 (1980):  703-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA "A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients." Can J Psychiatry 33 (1988):  590-4|Ayd FJ, Jr "Long-term treatment of chronic depression: 15-year experience with doxepin HCl." J Clin Psychiatry 45 (1984):  39-46|Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967):  1112-3|Gershon S "Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population." Psychopathology 17 (1984):  39-50|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness." Aust N Z J Psychiatry 27 (1993):  49-55|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Rosen J, Pollock BG, Altieri LP, Jonas EA "Treatment of nortriptyline''s side effects in elderly patients: a double-blind study of bethanechol." Am J Psychiatry 150 (1993):  1249-51|Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990):  926-32|Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989):  132-4|Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987):  877-9|Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982):  215-6|Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990):  122-4|Claghorn JL, Feighner JP "A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression." J Clin Psychopharmacol 13 (1993):  S23-7|Ritch R, Krupin T, Henry C, Kurata F "Oral imipramine and acute angle closure glaucoma." Arch Ophthalmol 112 (1994):  67-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40961, 11056, 'Clomipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'Remick RA, Campos PE, Misri S, Miles JE, Van Wyck, Fleet J "A comparison of the safety and efficacy of buproprion HCL and amitriptyline HCL in depressed outpatients." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  523-7|Guy W, McEvoy JM, Ban TA, Wilson WH, Pate K "A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology." Pharmacotherapy 3 (1983):  45-51|Bryant SG, Fisher S, Kluge RM "Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system." J Clin Psychopharmacol 7 (1987):  78-82|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Rudorfer MV, Young RC "Anticholinergic effects and plasma desipramine levels." Clin Pharmacol Ther 28 (1980):  703-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA "A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients." Can J Psychiatry 33 (1988):  590-4|Ayd FJ, Jr "Long-term treatment of chronic depression: 15-year experience with doxepin HCl." J Clin Psychiatry 45 (1984):  39-46|Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967):  1112-3|Gershon S "Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population." Psychopathology 17 (1984):  39-50|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness." Aust N Z J Psychiatry 27 (1993):  49-55|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Rosen J, Pollock BG, Altieri LP, Jonas EA "Treatment of nortriptyline''s side effects in elderly patients: a double-blind study of bethanechol." Am J Psychiatry 150 (1993):  1249-51|Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990):  926-32|Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989):  132-4|Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987):  877-9|Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982):  215-6|Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990):  122-4|Claghorn JL, Feighner JP "A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression." J Clin Psychopharmacol 13 (1993):  S23-7|Ritch R, Krupin T, Henry C, Kurata F "Oral imipramine and acute angle closure glaucoma." Arch Ophthalmol 112 (1994):  67-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40962, 11059, 'Clomipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'Remick RA, Campos PE, Misri S, Miles JE, Van Wyck, Fleet J "A comparison of the safety and efficacy of buproprion HCL and amitriptyline HCL in depressed outpatients." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  523-7|Guy W, McEvoy JM, Ban TA, Wilson WH, Pate K "A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology." Pharmacotherapy 3 (1983):  45-51|Bryant SG, Fisher S, Kluge RM "Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system." J Clin Psychopharmacol 7 (1987):  78-82|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Rudorfer MV, Young RC "Anticholinergic effects and plasma desipramine levels." Clin Pharmacol Ther 28 (1980):  703-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA "A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients." Can J Psychiatry 33 (1988):  590-4|Ayd FJ, Jr "Long-term treatment of chronic depression: 15-year experience with doxepin HCl." J Clin Psychiatry 45 (1984):  39-46|Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967):  1112-3|Gershon S "Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population." Psychopathology 17 (1984):  39-50|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness." Aust N Z J Psychiatry 27 (1993):  49-55|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Rosen J, Pollock BG, Altieri LP, Jonas EA "Treatment of nortriptyline''s side effects in elderly patients: a double-blind study of bethanechol." Am J Psychiatry 150 (1993):  1249-51|Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990):  926-32|Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989):  132-4|Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987):  877-9|Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982):  215-6|Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990):  122-4|Claghorn JL, Feighner JP "A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression." J Clin Psychopharmacol 13 (1993):  S23-7|Ritch R, Krupin T, Henry C, Kurata F "Oral imipramine and acute angle closure glaucoma." Arch Ophthalmol 112 (1994):  67-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40963, 14090, 'Clomipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'Remick RA, Campos PE, Misri S, Miles JE, Van Wyck, Fleet J "A comparison of the safety and efficacy of buproprion HCL and amitriptyline HCL in depressed outpatients." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  523-7|Guy W, McEvoy JM, Ban TA, Wilson WH, Pate K "A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology." Pharmacotherapy 3 (1983):  45-51|Bryant SG, Fisher S, Kluge RM "Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system." J Clin Psychopharmacol 7 (1987):  78-82|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Rudorfer MV, Young RC "Anticholinergic effects and plasma desipramine levels." Clin Pharmacol Ther 28 (1980):  703-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA "A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients." Can J Psychiatry 33 (1988):  590-4|Ayd FJ, Jr "Long-term treatment of chronic depression: 15-year experience with doxepin HCl." J Clin Psychiatry 45 (1984):  39-46|Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967):  1112-3|Gershon S "Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population." Psychopathology 17 (1984):  39-50|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness." Aust N Z J Psychiatry 27 (1993):  49-55|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Rosen J, Pollock BG, Altieri LP, Jonas EA "Treatment of nortriptyline''s side effects in elderly patients: a double-blind study of bethanechol." Am J Psychiatry 150 (1993):  1249-51|Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990):  926-32|Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989):  132-4|Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987):  877-9|Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982):  215-6|Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990):  122-4|Claghorn JL, Feighner JP "A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression." J Clin Psychopharmacol 13 (1993):  S23-7|Ritch R, Krupin T, Henry C, Kurata F "Oral imipramine and acute angle closure glaucoma." Arch Ophthalmol 112 (1994):  67-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40964, 14091, 'Clomipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'Remick RA, Campos PE, Misri S, Miles JE, Van Wyck, Fleet J "A comparison of the safety and efficacy of buproprion HCL and amitriptyline HCL in depressed outpatients." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  523-7|Guy W, McEvoy JM, Ban TA, Wilson WH, Pate K "A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology." Pharmacotherapy 3 (1983):  45-51|Bryant SG, Fisher S, Kluge RM "Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system." J Clin Psychopharmacol 7 (1987):  78-82|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Rudorfer MV, Young RC "Anticholinergic effects and plasma desipramine levels." Clin Pharmacol Ther 28 (1980):  703-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA "A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients." Can J Psychiatry 33 (1988):  590-4|Ayd FJ, Jr "Long-term treatment of chronic depression: 15-year experience with doxepin HCl." J Clin Psychiatry 45 (1984):  39-46|Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967):  1112-3|Gershon S "Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population." Psychopathology 17 (1984):  39-50|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness." Aust N Z J Psychiatry 27 (1993):  49-55|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Rosen J, Pollock BG, Altieri LP, Jonas EA "Treatment of nortriptyline''s side effects in elderly patients: a double-blind study of bethanechol." Am J Psychiatry 150 (1993):  1249-51|Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990):  926-32|Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989):  132-4|Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987):  877-9|Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982):  215-6|Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990):  122-4|Claghorn JL, Feighner JP "A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression." J Clin Psychopharmacol 13 (1993):  S23-7|Ritch R, Krupin T, Henry C, Kurata F "Oral imipramine and acute angle closure glaucoma." Arch Ophthalmol 112 (1994):  67-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40965, 14103, 'Clomipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'Remick RA, Campos PE, Misri S, Miles JE, Van Wyck, Fleet J "A comparison of the safety and efficacy of buproprion HCL and amitriptyline HCL in depressed outpatients." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  523-7|Guy W, McEvoy JM, Ban TA, Wilson WH, Pate K "A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology." Pharmacotherapy 3 (1983):  45-51|Bryant SG, Fisher S, Kluge RM "Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system." J Clin Psychopharmacol 7 (1987):  78-82|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Rudorfer MV, Young RC "Anticholinergic effects and plasma desipramine levels." Clin Pharmacol Ther 28 (1980):  703-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA "A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients." Can J Psychiatry 33 (1988):  590-4|Ayd FJ, Jr "Long-term treatment of chronic depression: 15-year experience with doxepin HCl." J Clin Psychiatry 45 (1984):  39-46|Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967):  1112-3|Gershon S "Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population." Psychopathology 17 (1984):  39-50|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness." Aust N Z J Psychiatry 27 (1993):  49-55|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Rosen J, Pollock BG, Altieri LP, Jonas EA "Treatment of nortriptyline''s side effects in elderly patients: a double-blind study of bethanechol." Am J Psychiatry 150 (1993):  1249-51|Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990):  926-32|Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989):  132-4|Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987):  877-9|Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982):  215-6|Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990):  122-4|Claghorn JL, Feighner JP "A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression." J Clin Psychopharmacol 13 (1993):  S23-7|Ritch R, Krupin T, Henry C, Kurata F "Oral imipramine and acute angle closure glaucoma." Arch Ophthalmol 112 (1994):  67-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40966, 14104, 'Clomipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'Remick RA, Campos PE, Misri S, Miles JE, Van Wyck, Fleet J "A comparison of the safety and efficacy of buproprion HCL and amitriptyline HCL in depressed outpatients." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  523-7|Guy W, McEvoy JM, Ban TA, Wilson WH, Pate K "A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology." Pharmacotherapy 3 (1983):  45-51|Bryant SG, Fisher S, Kluge RM "Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system." J Clin Psychopharmacol 7 (1987):  78-82|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Rudorfer MV, Young RC "Anticholinergic effects and plasma desipramine levels." Clin Pharmacol Ther 28 (1980):  703-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA "A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients." Can J Psychiatry 33 (1988):  590-4|Ayd FJ, Jr "Long-term treatment of chronic depression: 15-year experience with doxepin HCl." J Clin Psychiatry 45 (1984):  39-46|Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967):  1112-3|Gershon S "Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population." Psychopathology 17 (1984):  39-50|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness." Aust N Z J Psychiatry 27 (1993):  49-55|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Rosen J, Pollock BG, Altieri LP, Jonas EA "Treatment of nortriptyline''s side effects in elderly patients: a double-blind study of bethanechol." Am J Psychiatry 150 (1993):  1249-51|Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990):  926-32|Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989):  132-4|Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987):  877-9|Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982):  215-6|Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990):  122-4|Claghorn JL, Feighner JP "A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression." J Clin Psychopharmacol 13 (1993):  S23-7|Ritch R, Krupin T, Henry C, Kurata F "Oral imipramine and acute angle closure glaucoma." Arch Ophthalmol 112 (1994):  67-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40967, 33730, 'Clomipramine', 'Anticholinergic Syndrome', 'Tricyclic and tetracyclic antidepressants (TCAs) have anticholinergic activity, to which elderly patients are particularly sensitive.  Tertiary amines such as amitriptyline and trimipramine tend to exhibit greater anticholinergic effects than other agents in the class.  Therapy with TCAs should be administered cautiously in patients with preexisting conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention or obstruction; angle-closure glaucoma, untreated intraocular hypertension, or uncontrolled primary open-angle glaucoma; and gastrointestinal obstructive disorders.  In patients with angle-closure glaucoma, even average doses can precipitate an attack.  Glaucoma should be treated and under control prior to initiation of therapy with TCAs, and intraocular pressure monitored during therapy.', '3', 'Remick RA, Campos PE, Misri S, Miles JE, Van Wyck, Fleet J "A comparison of the safety and efficacy of buproprion HCL and amitriptyline HCL in depressed outpatients." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982):  523-7|Guy W, McEvoy JM, Ban TA, Wilson WH, Pate K "A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology." Pharmacotherapy 3 (1983):  45-51|Bryant SG, Fisher S, Kluge RM "Long-term versus short-term amitriptyline side effects as measured by a postmarketing surveillance system." J Clin Psychopharmacol 7 (1987):  78-82|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Rudorfer MV, Young RC "Anticholinergic effects and plasma desipramine levels." Clin Pharmacol Ther 28 (1980):  703-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Remick RA, Keller FD, Buchanan RA, Gibson RE, Fleming JA "A comparison of the efficacy and safety of alprazolam and desipramine in depressed outpatients." Can J Psychiatry 33 (1988):  590-4|Ayd FJ, Jr "Long-term treatment of chronic depression: 15-year experience with doxepin HCl." J Clin Psychiatry 45 (1984):  39-46|Warnes H, Lehmann HE, Ban TA "Adynamic ileus during psychoactive medication: a report of three fatal and five severe cases." Can Med Assoc J 96 (1967):  1112-3|Gershon S "Comparative side effect profiles of trazodone and imipramine: special reference to the geriatric population." Psychopathology 17 (1984):  39-50|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Judd FK, Moore K, Norman TR, Burrows GD, Gupta RK, Parker G "A multicentre double blind trial of fluoxetine versus amitriptyline in the treatment of depressive illness." Aust N Z J Psychiatry 27 (1993):  49-55|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Rosen J, Pollock BG, Altieri LP, Jonas EA "Treatment of nortriptyline''s side effects in elderly patients: a double-blind study of bethanechol." Am J Psychiatry 150 (1993):  1249-51|Pigott TA, Pato MT, Bernstein SE, Grover GN, Hill JL, Tolliver TJ, Murphy DL "Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results." Arch Gen Psychiatry 47 (1990):  926-32|Guillibert E, Pelicier Y, Archambault JC, Chabannes JP, Clerc G, Desvilles M, Guibert M, Pagot R, Poisat JL, Thobie Y "A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients." Acta Psychiatr Scand Suppl 350 (1989):  132-4|Hermesh H, Aizenberg D, Weizman A, Lapidot M, Munitz H "Clomipramine-induced urinary dysfunction in an obsessive-compulsive adolescent." Drug Intell Clin Pharm 21 (1987):  877-9|Ananth J, Assalian P, Links PS "Intolerable side effects of clomipramine." J Clin Psychopharmacol 2 (1982):  215-6|Jenike MA, Baer L, Greist JH "Clomipramine versus fluoxetine in obsessive-compulsive disorder: a retrospective comparison of side effects and efficacy." J Clin Psychopharmacol 10 (1990):  122-4|Claghorn JL, Feighner JP "A double-blind comparison of paroxetine with imipramine in the long-term treatment of depression." J Clin Psychopharmacol 13 (1993):  S23-7|Ritch R, Krupin T, Henry C, Kurata F "Oral imipramine and acute angle closure glaucoma." Arch Ophthalmol 112 (1994):  67-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40968, 720, 'Clomipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40969, 11056, 'Clomipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40970, 11059, 'Clomipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40971, 14090, 'Clomipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40972, 14091, 'Clomipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40973, 14103, 'Clomipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40974, 14104, 'Clomipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40975, 33730, 'Clomipramine', 'Cardiovascular Diseases', 'Tricyclic and tetracyclic antidepressants (TCAs) may cause orthostatic hypotension, reflex tachycardia, syncope, and dizziness, particularly during initiation of therapy or rapid escalation of dosage.  Imipramine appears to have the greatest propensity to induce these effects, while secondary amines such as nortriptyline may do so less frequently.  Tolerance to the hypotensive effects often develops after a few doses to a few weeks.  Rarely, collapse and sudden death have occurred secondary to severe hypotension.  Other reported adverse cardiovascular effects include tachycardia, arrhythmias, heart block, hypertension, thrombosis, thrombophlebitis, myocardial infarction, strokes, congestive heart failure, and ECG abnormalities such as PR and QT interval prolongation.  Therapy with TCAs should be avoided during the acute recovery phase following myocardial infarction, and should be administered only with extreme caution in patients with hyperthyroidism, a history of cardiovascular or cerebrovascular disease, or a predisposition to hypotension.  Close monitoring of cardiovascular status, including ECG changes, is recommended at all dosages.  Many of the newer antidepressants, including bupropion and the selective serotonin reuptake inhibitors (SSRIs), are considerably less or minimally cardiotoxic and may be appropriate alternatives.', '3', 'Robinson DS, Nies A, Corcella J, Cooper TB, Spencer C, Kefover R "Cardiovascular effects of phenelzine and amitriptyline in depressed outpatients." J Clin Psychiatry 43 (1982):  8-15|Veith RC, Bloom V, Bielski R, Friedel RO "ECG effects of comparable plasma concentrations of desipramine and amitriptyline." J Clin Psychopharmacol 2 (1982):  394-8|Dunn FG "Malignant hypertension associated with use of amitriptyline hydrochloride." South Med J 75 (1982):  1124-5|Christensen P, Thomsen HY, Pedersen OL, et al. "Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients." Psychopharmacology (Berl) 87 (1985):  212-5|Pedersen JH, Sorensen JL "Therapeutic effect and side effects in patients with endogenous depression treated with oral nortriptyline once a day." Neuropsychobiology 6 (1980):  42-7|Roose SP, Glassman AH, Siris SG, Walsh BT, Bruno RL, Wright LB "Comparison of imipramine- and nortriptyline-induced orthostatic hypotension: a meaningful difference." J Clin Psychopharmacol 1 (1981):  316-9|Young RC, Alexopoulos GS, Shamoian CA, Dhar AK, Kutt H "Heart failure associated with high plasma 10-hydroxynortriptyline levels." Am J Psychiatry 141 (1984):  432-3|Georgotas A, McCue RE, Hapworth W, et al. "Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly." Biol Psychiatry 21 (1986):  1155-66|Gross JS, Zwerin G "Left bundle branch block developing in a patient with sub-therapeutic nortriptyline levels: a case report." J Am Geriatr Soc 39 (1991):  1006-7|Rudorfer MV, Young RC "Desipramine: cardiovascular effects and plasma levels." Am J Psychiatry 137 (1980):  984-6|Nelson JC, Jatlow PI, Bock J, Quinlan DM, Bowes MB "Major adverse reactions during desipramine treatment." Arch Gen Psychiatry 39 (1982):  1055-61|Carpenter P, Gobel FL, Hulsing DJ "Desipramine cardiac toxicity." Minn Med 65 (1982):  231-4|Luchins DJ "Review of clinical and animal studies comparing the cardiovascular effects of doxepin and other tricyclic antidepressants." Am J Psychiatry 140 (1983):  1006-9|Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EG "Is doxepin a safer tricyclic for the heart?" J Clin Psychiatry 52 (1991):  338-41|Burrows GD, Vohra J, Hunt D, Sloman JG, Scoggins BA, Davies B "Cardiac effects of different tricyclic antidepressant drugs." Br J Psychiatry 129 (1976):  335-41|Linnoila M, Jobson KO, Gilliam JH, Paine RL "Effects of doxepin on blood pressure and heart rate in patients with primary major affective disorder ." J Clin Psychopharmacol 2 (1982):  433-4|Strasberg B, Coelho A, Welch W, Swiryn S, Bauernfeind R, Rosen K "Doxepin induced torsade de pointes." Pacing Clin Electrophysiol 5 (1982):  873-7|Appelbaum PS, Kapoor W "Imipramine-induced vasospasm: a case report." Am J Psychiatry 140 (1983):  913-5|Kantor SJ, Glassman AH, Bigger JT, Jr  Perel JM, Giardina EV "The cardiac effects of therapeutic plasma concentrations of imipramine." Am J Psychiatry 135 (1978):  534-8|Ramanathan KB, Davidson C "Cardiac arrhythmia and imipramine therapy." Br Med J 1 (1975):  661-2|"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|Bluhm RE, Wilkinson GR, Shelton R, Branch RA "Genetically determined drug-metabolizing activity and desipramine- associated cardiotoxicity: a case report." Clin Pharmacol Ther 53 (1993):  89-95|Laird LK, Lydiard RB, Morton WA, Steele TE, Kellner C, Thompson NM, Ballenger JC "Cardiovascular effects of imipramine, fluvoxamine, and placebo in depressed outpatients." J Clin Psychiatry 54 (1993):  224-8|Feighner JP, Cohn JB, Fabre LF, Jr  Fieve RR, Mendels J, Shrivastava RK, Dunbar GC "A study comparing paroxetine placebo and imipramine in depressed patients." J Affect Disord 28 (1993):  71-9|Van Sweden B "Rebound antidepressant cardiac arrhythmia." Biol Psychiatry 24 (1988):  363-4|Faravelli C, Brat A, Marchetti G, Franchi F, Padeletti L, Michelucci A, Pastorino A "Cardiac effects of clomipramine treatment. ECG and left ventricular systolic time intervals." Neuropsychobiology 9 (1983):  113-8|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|Roos JC "Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine." Br J Clin Pharmacol 15 Suppl 3 (1983):  s439-45|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Talbert RL, Yee GC, DiPiro JT, Matzke GR, Posey LM, Wells BG "Pharmacotherapy: A Pathophysiologic Approach" Stamford, CT: Appleton & Lange  (1999):|Upward JW, Edwards JG, Goldie A, Waller DG "Comparative effects of fluoxetine and amitriptyline on cardiac function." Br J Clin Pharmacol 26 (1988):  399-402', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40976, 720, 'Clomipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40977, 11056, 'Clomipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40978, 11059, 'Clomipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40979, 14090, 'Clomipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40980, 14091, 'Clomipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40981, 14103, 'Clomipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40982, 14104, 'Clomipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40983, 33730, 'Clomipramine', 'Pheochromocytoma', 'Tricyclic and tetracyclic antidepressants (TCAs) may potentiate the effects of circulating catecholamines.  Enhanced sympathetic activity can provoke hypertensive crises in patients with pheochromocytoma or other tumors of the adrenal medulla, such as some neuroblastomas.  Therapy with TCAs should be administered cautiously in patients with these tumors.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Sinequan (doxepin)." Roerig Division  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Remeron (mirtazapine)." Organon  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Ludiomil (maprotiline)." Ciba-Geigy Pharmaceuticals  (2001):|Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD "Harrison''s Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division  (1998):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40984, 720, 'Clomipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40985, 11056, 'Clomipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40986, 11059, 'Clomipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40987, 14090, 'Clomipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40988, 14091, 'Clomipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40989, 14103, 'Clomipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40990, 14104, 'Clomipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40991, 33730, 'Clomipramine', 'Acute Myocardial Infarction Recovery', 'The use of most tricyclic antidepressants is contraindicated in patients that are going through the acute recovery period after a myocardial infarction.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40992, 720, 'Clomipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40993, 11056, 'Clomipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40994, 11059, 'Clomipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40995, 14090, 'Clomipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40996, 14091, 'Clomipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40997, 14103, 'Clomipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40998, 14104, 'Clomipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (40999, 33730, 'Clomipramine', 'Depressive Disorder', 'Adult and pediatric patients with depression may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41000, 720, 'Clomipramine', 'Epilepsy', 'Tricyclic antidepressants (TCAs), can lower the seizure threshold and trigger seizures.  These drugs should be used with extreme caution in patients with a history of seizures, or other predisposing factors, such as head trauma, CNS abnormalities, and alcoholism.  Daily dose restrictions might apply for specific antidepressants.  Physicians are encouraged to get additional dosing recommendations on the manufacturer''s prescribing information.', '3', '"Product Information. Pamelor (nortriptyline)." Sandoz Pharmaceuticals Corporation  (2002):|"Product Information. Elavil (amitriptyline)." Stuart Pharmaceuticals  (2002):|"Product Information. Norpramin (desipramine)." Hoechst Marion Roussel  (2002):|"Product Information. Tofranil (imipramine)." Novartis Pharmaceuticals  (2002):|"Product Information. Anafranil (clomipramine)." Basel Pharmaceuticals  (2001):|"Product Information. Asendin (amoxapine)." Lederle Laboratories  (2001):|"Product Information. Surmontil (trimipramine)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Vivactil (protriptyline)." Merck & Co., Inc  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30', 'DDInter', 0);
